On March 27, 2020 Guangzhou XlifeSciences, a partner of GenScript ProBio (GenScript’s CDMO segment) reported that the early phase clinical trial of TAEST16001 project has been started (Press release, GenScript, MAR 27, 2020, View Source [SID1234555958]). GenScript ProBio extends congratulations on this.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This clinical trial project is China’s first TCR-T project targeted at solid tumor therapy, marking a milestone in immunotherapy in China. In 2019, XlifeSciences entrusted TCR-T products with complete independent intellectual property rights to GenScript ProBio. It is the first cooperation project between the parties, where GenScript ProBio works on plasmid and virus process development and clinical manufacturing and will be further responsible for commercial manufacturing.
"We congratulate XLifeSciences on the successful launch of TAEST16001 early phase clinical trial, which marks a milestone in the industry," said Dr. Brian Min, CEO of GenScript ProBio. "We are honored to offer technology and manufacturing support in such a meaningful project. With a one-stop high-quality plasmid and virus platform, GenScript ProBio facilitates XLifeSciences to complete all pre-clinical CMC research for IND filing. We will continue to follow up on the clinical trial. We wish that the clinical project proceeds smoothly so as to relieve patients from pain as soon as possible. We are optimistic about the prospects of the project. As China’s first company that has built the plasmid facility for gene and cell therapy, GenScript ProBio has well-established technological platform and quality system, and is capable of providing quality services to more customers.